

JO 10 Rec'd PCT/PTO 11 MAR 2002

Practitioner's Docket No. 56212 (71526)

09/889,379  
ATTEND

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: H. Sugiyama et al.  
Application No.: 09/889,379  
Filed: July 16, 2001  
For: DEVELOPMENT OF METHOD FOR SCREENING  
PHYSIOLOGICALLY ACTIVE PYRROLE IMADOLE DERIVATIVE

Assistant Commissioner for Patents  
Washington, D.C. 20231  
BOX: PCT

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,  
AND/OR AMENDMENT PERTAINING THERETO  
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE  
AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1.  This replies to the Office Letter DATED February 11, 2002.

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*  
(When using Express Mail, the Express Mail label number is mandatory;

Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)  
 with sufficient postage as first class mail.

37 C.F.R. SECTION 1.10\*

as "Express Mail Post Office to Address"  
Mailing Label No. EL932681052US  
(mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office (703) \_\_\_\_\_.

Susan M Dillon

Signature

Susan M. Dillon

(type or print name of person certifying)

Date: 3/11/02

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).

"Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**NOTE:** *If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.*

A copy of the Office Letter is enclosed.

### **IDENTIFICATION OF PERSON MAKING STATEMENT**

2. I, Peter F. Corless

*(type or print name of person signing below)*

state the following:

### **ITEMS BEING SUBMITTED**

3. Submitted herewith is/are:

*(check each item as applicable)*

- A.  "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B.  An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C.  A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D.  Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.: 0 /

Filed:

For:

Group No.:

Examiner:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form  
(other application)

"Sequence Identifier"  
(this application)

*NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. Section 1.821(e).*

E.  A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).

Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

F.  Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"  
AND COMPUTER READABLE COPY ARE THE SAME  
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

*(complete applicable item A and/or B)*

A.  Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B.  All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

**STATUS**

5. Applicant is

a small entity.  
 other than a small entity.

**EXTENSION OF TERM**

6.

*NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.*

*If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period*

*unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).*

NOTE: See 37 C.F.R. Section 1.645 for extensions of time in interference proceedings and 37 C.F.R. Section 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

*(complete (a) or (b) as applicable)*

(a)  [ ] Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than <u>small entity</u>	Fee for <u>small entity</u>
[ ] one month	\$ 110.00	\$ 55.00
[ ] two months	\$ 400.00	\$ 200.00
[ ] three months	\$ 920.00	\$ 460.00
[ ] four months	\$1,440.00	\$ 720.00

Fee \$ \_\_\_\_\_

If an additional extension of time is required, please consider this a petition therefor.

*(check and complete the next item, if applicable)*

[ ] An extension for \_\_\_\_\_ months has already been secured, and the fee paid therefor of \$ \_\_\_\_\_ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$ \_\_\_\_\_

OR

(b)  [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

#### FEE PAYMENT

8.  [ ] Attached is a check in the sum of \$ \_\_\_\_\_.

[ ] Charge Account No. \_\_\_\_\_ the sum of \$ \_\_\_\_\_.  
A duplicate of this transmittal is attached.

#### FEE DEFICIENCY

(Submission-Nucleotide and/or Amino Acid Sequence—page 4 of 5)

9.

**NOTE:** *If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.*

10.  If any additional extension and/or fee is required, charge Account No. 04-1105.

**SIGNATURE(s)**

Peter F. Corless

(type or print name of person signing statement)

**Signature**

3/11/02

Date

EDWARDS & ANGELL, LLP  
P.O. Box 9169

---

P.O. Address of Signatory

Boston, MA 02209

*(If applicable)*

Tel. No.: (617) 439-4444

Reg. No. 33 860

Reg. No. 55,800

- Inventor
- Assignee of complete interest
- Person authorized to sign on behalf of assignee
- Practitioner of record
- Filed under Rule 34(a)
- Registration No.
- Other

*(complete the following, if applicable)*

*(type name of assignee)*

**Address of assignee**

**Title of person authorized to sign on behalf of assignee**

A "STATEMENT UNDER 37 C.F.R. Section 3.73(b)" is attached.

Assignment recorded in PTO on

Assignment recorded in F10 on \_\_\_\_\_  
Reel \_\_\_\_\_ Frame \_\_\_\_\_



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.	
09/889,379	Hiroshi Sugiyama	56212 (71526)	
<b>RECEIVED</b> FEB 14 2002 EDWARDS & ANGELL LLP DIKE BRONSTEIN ROBERTS CUSHMAN		INTERNATIONAL APPLICATION NO. PCT/JP00/07992	
		I.A. FILING DATE 11/13/2000	PRIORITY DATE 11/16/1999

Peter F Corless  
Dike Bronstein Roberts & Cushman  
Edwards & Angell  
P.O. Box 9169  
Boston, MA 02209

CONFIRMATION NO. 2742  
371 FORMALITIES LETTER



\*OC00000007453218\*

Date Mailed: 02/11/2002

### NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- U.S. Basic National Fee
- Priority Document
- Assignee Statement
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination

*Sequence Listing*

Edwards & Angell LLP

Dike, Bronstein, Roberts & Cushman

101 Federal St. Boston, MA 02110

Date Rec'd 2/14/02

Docketed For Mac 10 - Apr 10, 2002

By LLP

Approved       

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

Additionally the following defects have been observed:

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/889,379	Hirosi Sugiyama	56212 (71526)

INTERNATIONAL APPLICATION NO.

PCT/JP00/07992

I.A. FILING DATE	PRIORITY DATE
11/13/2000	11/16/1999

**CONFIRMATION NO. 2742**  
**371 FORMALITIES LETTER**



\*OC000000007453218\*

Date Mailed: 02/11/2002

### NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- U.S. Basic National Fee
- Priority Document
- Assignee Statement
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

Additionally the following defects have been observed:

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the

computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

■ **APPLICANT MUST PROVIDE:**

- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- Additional claim fees of **\$18** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

**SUMMARY OF FEES DUE:**

Total additional fees required for this application is **\$18** for a Large Entity:

- Total additional claim fee(s) for this application is **\$18**
  - **\$18** for **5** total claims over 20.
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)


*A copy of this notice **MUST** be returned with the response.*

WINSTON M ALVARADO

Telephone: (703) 305-6421

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/889,379	PCT/JP00/07992	56212 (71526)



## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/889,379  
Source: PUR/09  
Date Processed by STIC: 1/24/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

*MAIL THIS COPY WITH  
THE GOS FOR 11.*

**Raw Sequence Listing Error Summary**

**ERROR DETECTED**      **SUGGESTED CORRECTION**      **SERIAL NUMBER:** 09/889,379

**ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE**

1  Wrapped Nucleic  
       Wrapped Aminos      The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2  Invalid Line Length      The rules require that a line not exceed 72 characters in length. This includes white spaces.

3  Misaligned Amino  
      Numbering      The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4  Non-ASCII      The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5  Variable Length      Sequence(s) \_\_\_\_\_ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6  PatentIn 2.0  
      "bug"      A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) \_\_\_\_\_. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**

7  Skipped Sequences  
      (OLD RULES)      Sequence(s) \_\_\_\_\_ missing. If intentional, please insert the following lines for each skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
This sequence is intentionally skipped  
  
Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8  Skipped Sequences  
      (NEW RULES)      Sequence(s) \_\_\_\_\_ missing. If Intentional, please insert the following lines for each skipped sequence.  
<210> sequence id number  
<400> sequence id number  
000

9  Use of n's or Xaa's  
      (NEW RULES)      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10  Invalid <213>  
      Response      Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

11  Use of <220>  
      - - -      Sequence(s) 1-4 missing the <220> "Feature" and associated numeric identifiers and responses.  
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12  PatentIn 2.0  
      "bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13  Misuse of n      n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.



PCT09

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/889,379

DATE: 01/24/2002

TIME: 12:26:55

Input Set : A:\56212 sequence listing.txt  
Output Set: N:\CRF3\01242002\I889379.rawDoes Not Comply  
Corrected Diskette Needed

3 <110> APPLICANT: Japan Science And Technology Corporation  
 W--> 4 <120> TITLE OF INVENTION: Method for screening biologically active pyrrole-imidazole derivatives.

W--&gt; 5 &lt;130&gt; FILE REFERENCE: PA902087

W--&gt; 7 &lt;140&gt; CURRENT APPLICATION NUMBER: US/09/889,379

W--&gt; 7 &lt;141&gt; CURRENT FILING DATE: 2001-12-10

7 &lt;160&gt; NUMBER OF SEQ ID NOS: 4

10 &lt;210&gt; SEQ ID NO: 1

11 &lt;211&gt; LENGTH: 27

12 &lt;212&gt; TYPE: DNA

13 &lt;213&gt; ORGANISM: Artificial Sequence

W--&gt; 15 &lt;220&gt; FEATURE:

W--&gt; 15 &lt;223&gt; OTHER INFORMATION:

15 &lt;400&gt; SEQUENCE: 1

16 ctgacgagca tcacaaaaat cgacgct

27

19 &lt;210&gt; SEQ ID NO: 2

20 &lt;211&gt; LENGTH: 27

21 &lt;212&gt; TYPE: DNA

22 &lt;213&gt; ORGANISM: Artificial Sequence

W--&gt; 24 &lt;220&gt; FEATURE:

W--&gt; 24 &lt;223&gt; OTHER INFORMATION:

24 &lt;400&gt; SEQUENCE: 2

25 agcgtcgatt tttgtatgc tcgtcag

27

28 &lt;210&gt; SEQ ID NO: 3

29 &lt;211&gt; LENGTH: 450

30 &lt;212&gt; TYPE: DNA

31 &lt;213&gt; ORGANISM: Unknown

same env

W--&gt; 33 &lt;220&gt; FEATURE:

W--&gt; 33 &lt;223&gt; OTHER INFORMATION:

33 &lt;400&gt; SEQUENCE: 3

34 agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggcaggaa

60

35 ccgtaaaaag gccgcgttgc tggcgaaaaa ccataggctc cgccccctg acgagcatca

120

36 caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc

180

37 gttccccctt ggaagctccc tcgtgcgtc tcctgttccg accctgcccgc ttaccggata

240

38 cctgtccggc ttctccctt cggaaagcgt ggccgtttct caatgctcac gctgttaggta

300

39 tctcgttcg gtgttaggtcg ttgcgtccaa gctgggctgt gtgcacgaac ccccccgttca

360

40 gccccaccgc tgccgttat cggtaacta tcgtcttgag tccaaacccgg taagacacga

420

41 ctatcgcca ctggcagcag ccactggtaa

450

44 &lt;210&gt; SEQ ID NO: 4

45 &lt;211&gt; LENGTH: 450

46 &lt;212&gt; TYPE: DNA

47 &lt;213&gt; ORGANISM: Unknown

same

W--&gt; 49 &lt;220&gt; FEATURE:

W--&gt; 49 &lt;223&gt; OTHER INFORMATION:

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/889,379

DATE: 01/24/2002  
TIME: 12:26:55

Input Set : A:\56212 sequence listing.txt  
Output Set: N:\CRF3\01242002\I889379.raw

49 <400> SEQUENCE: 4

50	ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttggga ctcaagacga	60
51	tagttaccgg ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac acagccacg	120
52	ttggagcga a gacccatcac cgaactcaga tacctacagc gtgagcattt agaaagcgcc	180
53	acgatccccg a a gggagaaaa ggccggacagg tatccgtaa gcggcagggt cggAACAGGA	240
54	gagcgcacga gggagctcc a gggggaaac gcctggatc tttatagtcc tgcgggttt	300
55	cgcccacctct gacttgcgc tcgatTTTG t gatgctcgt caggggggcg gagcctatgg	360
56	aaaaacgcca gcaacgcggc cttttacgg ttcctggct tttgctggcc ttttgcac	420
57	atgttcttcc tgcgttatac ccctgattct	450

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/889,379

DATE: 01/24/2002

TIME: 12:26:56

Input Set : A:\56212 sequence listing.txt  
Output Set: N:\CRF3\01242002\I889379.raw

L:4 M:283 W: Missing Blank Line separator, <120> field identifier  
L:5 M:283 W: Missing Blank Line separator, <130> field identifier  
L:7 M:270 C: Current Application Number differs, Replaced Current Application No  
L:7 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:15 M:258 W: Mandatory Feature missing, <220> FEATURE:  
L:15 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:  
L:24 M:258 W: Mandatory Feature missing, <220> FEATURE:  
L:24 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:  
L:33 M:258 W: Mandatory Feature missing, <220> FEATURE:  
L:33 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:  
L:49 M:258 W: Mandatory Feature missing, <220> FEATURE:  
L:49 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION: